Goltzman D
Department of Medicine, McGill University, Montreal, QC, Canada.
Department of Physiology, McGill University, Montreal, QC, Canada.
Histochem Cell Biol. 2018 Apr;149(4):305-312. doi: 10.1007/s00418-018-1648-y. Epub 2018 Feb 12.
Vitamin D, synthesized in the skin or absorbed from the diet, undergoes multi-step enzymatic conversion to its active form, 1,25-dihydroxy vitamin D [1,25(OH)D], followed by interaction with the vitamin D receptor (VDR), to modulate target gene expression. Loss-of function mutations in the genes encoding the enzymes regulating these processes, or in the VDR, result in human diseases, which have demonstrated the paramount role of 1,25(OH)D in mineral and skeletal homeostasis. Mouse genetics has been used to create disease phenocopies which have produced considerable insight into the mechanisms of 1,25(OH)D regulation of mineral and skeletal metabolism. Hypophosphatemia resulting from 1,25(OH)D deficiency or resistance can inhibit apoptosis in hypertrophic chondrocytes leading to abnormal development of the cartilaginous growth plate in rickets. Decreased 1,25(OH)D may also cause decreased vascular invasion associated with reduced chondroclast and osteoclast activity and thereby contribute to growth plate abnormalities. Reduced 1,25(OH)D-mediated intestinal and renal calcium transport can reduce calcium availability, increase parathyroid hormone secretion and phosphaturia, and impair mineral availability for normal matrix mineralization, resulting in reduced growth plate mineralization and osteomalacia. 1,25(OH)D may exert an anabolic effect in bone, apparently via the VDR in mature osteoblasts, by increasing osteoblast activity and reducing osteoclast activity. High ambient levels of exogenous 1,25(OH)D, or of elevated endogenous 1,25(OH)D in the presence of reduced calcium balance, can enhance bone resorption, and apparently prevent mineral deposition in bone. These actions demonstrate the critical role of vitamin D in regulating skeletal homeostasis both indirectly and directly via the 1,25(OH)D/VDR system.
维生素D可在皮肤中合成或从饮食中吸收,经过多步酶促转化成为其活性形式1,25 - 二羟基维生素D [1,25(OH)D],随后与维生素D受体(VDR)相互作用,以调节靶基因表达。编码调节这些过程的酶的基因或VDR中的功能丧失突变会导致人类疾病,这已证明1,25(OH)D在矿物质和骨骼稳态中起至关重要的作用。小鼠遗传学已被用于创建疾病表型模拟,这为深入了解1,25(OH)D对矿物质和骨骼代谢的调节机制提供了大量信息。由1,25(OH)D缺乏或抵抗引起的低磷血症可抑制肥大软骨细胞的凋亡,导致佝偻病中软骨生长板发育异常。1,25(OH)D降低还可能导致与软骨破骨细胞和成骨细胞活性降低相关的血管侵入减少,从而导致生长板异常。1,25(OH)D介导的肠道和肾脏钙转运减少会降低钙的可用性,增加甲状旁腺激素分泌和磷尿,并损害正常基质矿化的矿物质可用性,导致生长板矿化减少和骨软化症。1,25(OH)D可能通过增加成骨细胞活性和降低破骨细胞活性,显然是通过成熟成骨细胞中的VDR,在骨骼中发挥合成代谢作用。环境中外源性1,25(OH)D水平过高,或在钙平衡降低的情况下内源性1,25(OH)D升高,可增强骨吸收,并显然会阻止矿物质在骨骼中的沉积。这些作用表明维生素D通过1,25(OH)D/VDR系统间接和直接调节骨骼稳态中起着关键作用。